Bicara Therapeutics (NASDAQ:BCAX) Sets New 12-Month High – Here’s What Happened

Bicara Therapeutics Inc. (NASDAQ:BCAXGet Free Report) reached a new 52-week high during trading on Wednesday . The stock traded as high as $28.08 and last traded at $26.11, with a volume of 2883 shares trading hands. The stock had previously closed at $25.19.

Analyst Ratings Changes

A number of research firms have commented on BCAX. Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a report on Tuesday. They issued a “buy” rating and a $48.00 price objective for the company. TD Cowen assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating for the company. RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday. Morgan Stanley assumed coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 target price for the company. Finally, Stifel Nicolaus assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They set a “buy” rating and a $47.00 price target for the company. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Bicara Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $43.33.

View Our Latest Research Report on Bicara Therapeutics

Bicara Therapeutics Price Performance

Insider Activity at Bicara Therapeutics

In other Bicara Therapeutics news, Director Ra Capital Management, L.P. purchased 1,833,000 shares of the business’s stock in a transaction on Monday, September 16th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $32,994,000.00. Following the acquisition, the director now owns 4,303,418 shares of the company’s stock, valued at approximately $77,461,524. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. In other Bicara Therapeutics news, Director Ra Capital Management, L.P. purchased 1,833,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $32,994,000.00. Following the completion of the acquisition, the director now owns 4,303,418 shares of the company’s stock, valued at approximately $77,461,524. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder James E. Flynn bought 70,000 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $1,260,000.00. Following the purchase, the insider now owns 897,587 shares in the company, valued at approximately $16,156,566. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here.

Bicara Therapeutics Company Profile

(Get Free Report)

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

Recommended Stories

Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.